Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

被引：43

作者：

Arbour, Kathryn C. ^{[1
]}

Riely, Gregory J. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, 300 East 66th St, New York, NY 10065 USA

[2] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2017年 / 31卷 / 01期

关键词：

EML4-ALK rearrangement; Non-small cell lung cancer (NSCLC); Anaplastic lymphoma kinase inhibitors (ALK inhibitors); Crizotinib; Ceritinb; Alectinib; MUTATION CONFERS RESISTANCE; SELECTIVE ALK INHIBITOR; EML4-ALK FUSION GENE; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; EGFR; ADENOCARCINOMAS; ALECTINIB; CERITINIB;

D O I：

10.1016/j.hoc.2016.08.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small portion of patients with non-small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK-driven tumor formation. Patients with tumors harboring such rearrangements are highly sensitive to ALK inhibitors, such as crizotinib, ceritinib, and alectinib. Resistance to these kinase inhibitors occurs through several mechanisms, resulting in ongoing clinical challenges. This review summarizes the.biology of ALK-positive lung,cancer, methods for diagnosing ALK-positive NSCLC, current FDA-approved ALK inhibitors, mechanisms of resistance to ALK inhibition, and potential strategies to combat resistance.

引用

页码：101 / +

页数：12

共 55 条

[1]

[Anonymous], CRIZ TREAT PAT STAG

[2]

Arcila ME, 2015, J CLIN ONCOL, V33

[3] Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer [J].

Berge, Eamon M. ;

Lu, Xian ;

Maxson, Delee ;

Baron, Anna E. ;

Gadgeel, Shirish M. ;

Solomon, Benjamin J. ;

Doebele, Robert C. ;

Varella-Garcia, Maria ;

Camidge, D. Ross .

CLINICAL LUNG CANCER, 2013, 14 (06) :636-643

[4] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[5] Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling [J].

Chaft, Jamie E. ;

Arcila, Maria E. ;

Paik, Paul K. ;

Lau, Christopher ;

Riely, Gregory J. ;

Pietanza, M. Catherine ;

Zakowski, Maureen F. ;

Rusch, Valerie ;

Sima, Camelia S. ;

Ladanyi, Marc ;

Kris, Mark G. .

MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) :485-491

[6] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].

Choi, Young Lim ;

Soda, Manabu ;

Yamashita, Yoshihiro ;

Ueno, Toshihide ;

Takashima, Junpei ;

Nakajima, Takahiro ;

Yatabe, Yasushi ;

Takeuchi, Kengo ;

Hamada, Toru ;

Haruta, Hidenori ;

Ishikawa, Yuichi ;

Kimura, Hideki ;

Mitsudomi, Tetsuya ;

Tanio, Yoshiro ;

Mano, Hiroyuki .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739

[7] Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases [J].

Costa, Daniel B. ;

Shaw, Alice T. ;

Ou, Sai-Hong I. ;

Solomon, Benjamin J. ;

Riely, Gregory J. ;

Ahn, Myung-Ju ;

Zhou, Caicun ;

Shreeve, S. Martin ;

Selaru, Paulina ;

Polli, Anna ;

Schnell, Patrick ;

Wilner, Keith D. ;

Wiltshire, Robin ;

Camidge, D. Ross ;

Crino, Lucio .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1881-1888

[8] CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib [J].

Costa, Daniel B. ;

Kobayashi, Susumu ;

Pandya, Shuchi S. ;

Yeo, Wee-Lee ;

Shen, Zhongzhou ;

Tan, Weiwei ;

Wilner, Keith D. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :E443-E445

[9]

Crino L, 2016, J CLIN ONCOL

[10] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

← 1 2 3 4 5 6 →